AUSTIN, Texas, Nov. 17, 2020 /PRNewswire/ -- Aeglea
BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage
biotechnology company developing a new generation of human enzyme
therapeutics as innovative solutions for rare and other high-burden
diseases, today announced it will participate in fireside chats at
two investor conferences in December
2020.
Conference Details
Conference Name: Piper
Sandler 32nd Annual Virtual Healthcare
Conference
Conference Date: November 30 - December 3, 2020
Fireside Chat Date/Time: Available beginning November 23, 2020
Presenter: Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea's
president and chief executive officer
Conference Name: Evercore ISI 3rd Annual HealthCONx
Conference
Conference Date: December 1-3, 2020
Fireside Chat Date/Time: December 1,
2020 at 4:20 p.m. EST
Presenter: Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea's
president and chief executive officer
To access the live and archived webcasts, visit the
Presentations & Events section of the Company's website. Please
connect to the website at least 15 minutes prior to the
presentation to allow for any software download that may be
necessary. An archived version of the webcasts will also be
available through the Company's website for a limited time
following the conferences.
About Aeglea BioTherapeutics
Aeglea BioTherapeutics is a clinical-stage biotechnology company
redefining the potential of human enzyme therapeutics to benefit
people with rare and other high burden diseases. Aeglea's lead
product candidate, pegzilarginase, is in a pivotal Phase 3 trial
for the treatment of Arginase 1 Deficiency and has received both
Rare Pediatric Disease and Breakthrough Therapy Designation. The
Company initiated a Phase 1/2 clinical trial of ACN00177 for the
treatment of Homocystinuria in the second quarter of 2020. Aeglea
has an active discovery platform, with the most advanced program
for Cystinuria. For more information, please visit
http://aegleabio.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/aeglea-biotherapeutics-to-participate-in-two-upcoming-virtual-investor-conferences-301175289.html
SOURCE Aeglea BioTherapeutics, Inc.